DelveInsight’s, “Nonalcoholic Steatohepatitis- Pipeline Insight, 2023” report provides comprehensive insights about 100+ companies and 150+ pipeline drugs in the Nonalcoholic Steatohepatitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Got queries? Click here to know more about the Non-Alcoholic Steatohepatitis (NASH) Market Landscape.
Non-Alcoholic Steatohepatitis Overview
Nonalcoholic steatohepatitis is liver inflammation and damage caused by a fat buildup in the liver. It is part of a group of conditions called nonalcoholic fatty liver disease. Nonalcoholic fatty liver disease can be divided into the isolated fatty liver in which there is only accumulation of fat, and nonalcoholic steatohepatitis (NASH), in which there is fat, inflammation, and damage to liver cells. In NASH, there is an abnormal amount of fat in the liver cells, but, in addition, in NASH, there is inflammation within the liver, and, as a result, the liver cells are damaged, they die, and are replaced by scar tissue. NASH progresses to scarring and ultimately to cirrhosis, with all the complications of cirrhosis, for example, gastrointestinal bleeding, liver failure, and liver cancer.
- Non- Alcoholic Steatohepatitis prevelant cases
- Non – Alcoholic Steatohepatitis incident cases
- Non- Alcoholic Steatohepatitis diagnosed cases
- Non- Alcoholic Steatohepatitis treatment cases
- Madrigal Pharmaceuticals
- Cirius Therapeutics
- Ionis Pharmaceuticals
- NorthSea Therapeutics
- Rivus Pharmaceuticals
And many others
- HU 6
- HTD 1801
And many others
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States